Biocon is currently trading at Rs. 425.00, up by 5.10 points or 1.21% from its previous closing of Rs. 419.90 on the BSE.
The scrip opened at Rs. 428.05 and has touched a high and low of Rs. 429.90 and Rs. 424.20 respectively. So far 17355 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 553.70 on 04-Jul-2014 and a 52 week low of Rs. 402.45 on 07-Jan-2015.
Last one week high and low of the scrip stood at Rs. 430.00 and Rs. 402.45 respectively. The current market cap of the company is Rs. 8398.00 crore.
The promoters holding in the company stood at 61.02% while Institutions and Non-Institutions held 18.22% and 20.75% respectively.
Biocon has completed sale of 10% stake in its research arm Syngene for Rs 380 crore to IVF Trustee Company. In September, the company had announced that Mauritius-based private equity fund Silver Leaf Oak would acquire 10% stake in its research services arm Syngene International for Rs 380 crore from Biocon Research (BRL), a wholly-owned subsidiary of the Bangalore-based firm.
The deal had put the entire valuation of Syngene International, a wholly-owned subsidiary of Biocon, at Rs 3,800 crore.
Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: